Navigation Links
Champions Biotechnology signs exclusive agreement with Tel Aviv University for cancer drug

Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a U.S. Oncology drug development company with a predictive preclinical platform aimed at accelerating the development and enhancing the value of oncology drugs, has established an exclusive licensing agreement with Ramot at Tel Aviv University Ltd., Tel Aviv University's wholly owned technology transfer company.

The licensing agreement encompasses the development and commercialization of TAR-1, a single-chain antibody fragment in preclinical development that may have an advantage in treating cancer patients because of its high specificity and affinity to binding mutant p53 protein.

Under the terms of the agreement, Champions has obtained the worldwide rights to TAR-1 and is responsible for the further development of the compound. Champions will utilize its Biomerk Tumorgraft(TM) platform technology to evaluate the activity of TAR-1 and determine the best path forward for the compound in regards to indication, patient population and potential drug combinations. Ramot will receive an upfront payment and will be eligible to receive milestone payments and royalties if Champions chooses to continue the license terms, which will be determined based on results from testing TAR-1 in the predictive Tumorgraft platform.

Inhibits tumor growth

Prof. Beka Solomon from Tel Aviv University identified that TAR-1 binds to and restores the wild-type active conformation of mutant p53 protein with a high degree of specificity, leading to in vivo inhibition of tumor growth. Given the frequency of mutant p53 in cancer, TAR-1 has the potential to target a wide range of human cancers.

"Licensing TAR-1 demonstrates the progression of our strategy to build our own Tumorgraft-driven pipeline of oncology drugs, which we expect to yield improved clinical development success rates," said Guy Malchi, Champions Biotechnology's Head of Corporate Development and International Operations.

"We were impressed by the potential of TAR-1 and we are planning to continue to in-license oncology drug candidates with compelling science and to develop only those with positive Tumorgraft results." TAR-1 will undergo Tumorgraft testing as Champions completes Tumorgraft testing of its other oncology drug, SG410, a tubulin inhibitor.

"We are excited to work with Champions Biotechnology. Their predictive platform and experienced scientific and clinical team make them an ideal candidate to move TAR-1 forward into the clinic and on the path to commercialization," said Dr. Ze'ev Weinfeld, CEO, Ramot at Tel Aviv University Ltd.


Contact: George Hunka
American Friends of Tel Aviv University

Related medicine news :

1. Houston Dermatologists to Round Up for Sun Safety at World-Class LPGA Tour Championship
2. World Champion New York Yankees, BNY Mellon to be Honored as New York Blood Center Champions of Life
3. Planned Parenthood Advocacy Project Los Angeles County Celebrates Champions of Choice at Politics, Sex & Cocktails
4. Maldonado Medical LLC Champions Physician & Patient Rights for Better Reimbursement Schedules Nationwide
5. Illinois Dermatologists Tee Up for Sun Safety at Two World-Class Golf Championships
6. Mentors Who Support Students Receive TCWF Champions of Health Professions Diversity Award
7. The Byron Nelson: Championship Philosophy, Timeless Excellence
8. Champions Shawn Johnson & Phil Jackson Wear Energy Muse Jewelry
9. The Biggest Loser Champions Living Well
10. Insulet Applauds Employee for Bronze Medal Performance in World Blind Sailing Championships
11. The National Multiple Sclerosis Societys 35th Annual Dinner of Champions to Honor Summit Entertainments Rob Friedman
Post Your Comments:
Related Image:
Champions Biotechnology signs exclusive agreement with Tel Aviv University for cancer drug
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever ... Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation ... as home to some of the world’s leading providers of cereal and other breakfast ...
(Date:6/25/2016)... ... 2016 , ... Experts from the American Institutes for Research ... June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR experts ... planning, healthcare costs and patient and family engagement. , AIR researchers will be ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... -- Dehaier Medical Systems Ltd. (NASDAQ: DHRM ... sells medical devices and wearable sleep respiratory products in ... agreement with Hongyuan Supply Chain Management Co., Ltd. (hereinafter ... 2016, to develop Dehaier,s new Internet medical technology business. ... leverage Hongyuan Supply Chain,s sales platform to reach Dehaier,s ...
(Date:6/24/2016)... PUNE, India , June 24, 2016 ... "Pen Needles Market by Type (Standard Pen Needles, Safety ... 12mm), Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase ... published by MarketsandMarkets, This report studies the market for ... is expected to reach USD 2.81 Billion by 2021 ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
Breaking Medicine Technology: